drugset / Trial / NCT02062203

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

NCT02062203

Phase 1 Completed 50 enrolled Akebia Therapeutics
RandomizedCrossoverQuadruple-blindOther

Summary

The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.

Timeline

Start
2014-01
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject Vadadustat Small molecule Oral

Indications

No indication recorded.